124937-51-5 Category:
  • #LGM Pharma is a Tolterodine CAS# 124937-51-5 API supplier distributor based in the USA. Inquire about DMF, cGMP, price, availability, delivery, purity, and more.
  • #Questions? Call our customer API support number 1-(800)-881-8210.
  • #LGM Pharma offers this active ingredient but not the finished dosage forms.

Product Details:

  • CAS No: 124937-51-5
  • AHFC code: 26:12.0
  • Synonyms: Tolterodina [INN-Spanish] Tolterodine [INN] tolterodine extended release capsules Tolterodine L-Tartrate Tolterodine Tartrate Tolterodinum [INN-Latin] Tolterondine Tartrate
  • ATC Code: G04BD07
  • Chemical Formula: C16H20N4O3S
  • Molecular Weight: 325.4876
  • Assay/Purity: Typically NLT 98%
  • DrugBank: DB01036 (APRD00146)
  • SMILES: CC(C)N(CC[C,H](C1=CC=CC=C1)C1=C(O)C=CC(C)=C1)C(C)C
  • PubChem:
  • IUPAC: 2-[(1R)-3-[bis(propan-2-yl)amino]-1-phenylpropyl]-4-methylphenol

Additional Details

For the treatment of overactive bladder (with symptoms of urinary frequency, urgency, or urge incontinence).
Tolterodine is a competitive muscarinic receptor antagonist. Both urinary bladder contraction and salivation are mediated via cholinergic muscarinic receptors. After oral administration, tolterodine is metabolized in the liver, resulting in the formation of the 5-hydroxymethyl derivative, a major pharmacologically active metabolite. The 5-hydroxymethyl metabolite, which exhibits an antimuscarinic activity similar to that of tolterodine, contributes significantly to the therapeutic effect. Both tolterodine and the 5-hydroxymethyl metabolite exhibit a high specificity for muscarinic receptors, since both show negligible activity or affinity for other neurotransmitter receptors and other potential cellular targets, such as calcium channels. Tolterodine has a pronounced effect on bladder function. The main effects of tolterodine are an increase in residual urine, reflecting an incomplete emptying of the bladder, and a decrease in detrusor pressure, consistent with an antimuscarinic action on the lower urinary tract.
Mode of Action:
Both tolterodine and its active metabolite, 5-hydroxymethyltolterodine, act as competitive antagonists at muscarinic receptors. This antagonism results in inhibition of bladder contraction, decrease in detrusor pressure, and an incomplete emptying of the bladder.
General Reference:
Products currently covered by valid US Patents are offered for R&D use in accordance with 35 USC 271(e)+A13(1). Any patent infringement and resulting liability is solely at buyer risk.

API’s From Quality Manufacturers:

  • Cost effective materials based on specific requirements
  • Small quantities for initial research and larger development quantities towards product commercialization


  • Technical packages, letters of access to filed DMFs
  • Complete assistance in any regulatory filings
  • Top quality GMP certified manufacturers
  • Have necessary regulatory credentials


Related YouTube Videos